TARO - Taro Pharmaceutical Industries Ltd.

NYSE - NYSE Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
3/30/2019
3/30/2018
3/30/2017
3/30/2016
Total Revenue
678,448
669,893
661,913
879,387
950,751
Cost of Revenue
238,041
224,169
198,405
208,136
171,785
Gross Profit
440,407
445,724
463,508
671,251
778,966
Operating Expenses
Research Development
64,220
63,238
70,418
70,644
71,160
Selling General and Administrative
90,574
89,971
88,196
85,656
92,365
Total Operating Expenses
154,966
149,531
160,498
156,300
164,498
Operating Income or Loss
285,441
296,193
303,010
514,951
614,468
Interest Expense
-
256
304
131
473
Total Other Income/Expenses Net
32,139
27,119
-30,576
31,379
9,748
Income Before Tax
352,689
356,854
292,368
560,798
636,820
Income Tax Expense
78,092
74,732
81,954
103,780
95,313
Income from Continuing Operations
274,597
282,122
210,414
457,018
541,507
Net Income
274,301
281,777
211,150
456,356
540,932
Net Income available to common shareholders
274,301
281,777
211,150
456,356
540,932
Reported EPS
Basic
-
7.23
5.26
11.05
12.62
Diluted
-
7.23
5.26
11.05
12.62
Weighted average shares outstanding
Basic
-
38,990
40,155
41,301
42,832
Diluted
-
38,990
40,155
41,301
42,832
EBITDA
-
375,707
309,168
575,758
652,141